| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 14 Feb 2026 | 10 Feb 2026 |
| Quarterly Results. Parmax Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2026 ,inter alia, to consider and approve Unaudited Financial results for quarter and nine months ended on December 31, 2025. Outcome of Board meeting for Financial Results (As Per BSE Announcement Dated on: 14/02/2026) | ||
| Board Meeting | 17 Nov 2025 | 8 Nov 2025 |
| Parmax Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2025 inter alia to consider and approve For approval of Unaudited Financial results for quarter ended September 30 2025. Parmax Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 15/11/2025 ,inter alia, to consider and approve Reschedule of Board Meeting supposed to be held on November 14, 2025 (As Per BSE Announcement Dated on: 15/11/2025) The Board Meeting was initially rescheduled on November 15, 2025 and thenafter on today i.e. November 17, 2025 hence Board has approved the Unaudited Financial statements for quarter and half year ended on September 30, 2025 The Board Meeting was initially rescheduled on November 15, 2025 and thenafter on today i.e. November 17, 2025 hence Board has approved the Unaudited Financial statements for quarter and half year ended on September 30, 2025. The Board meeting for approval of Financial statements was rescheduled initially on November 15, 2025 and thenafter on today i.e. November 17, 2025. The Board has approved the unaudited financial results for quarter and half year ended on September 30, 2025 . (As Per BSE Announcement Dated on: 17/11/2025) | ||
| Board Meeting | 14 Aug 2025 | 8 Aug 2025 |
| Parmax Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2025 inter alia to consider and approve Board meeting to be held for Considering Unaudited Financial statements of the Company for Quarter ended June 30 2025 Approval of Financial results of Quarter ended 30th June 2025 (As Per BSE Announcement Dated on: 14.08.2025) | ||
| Board Meeting | 30 May 2025 | 21 May 2025 |
| Parmax Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2025 inter alia to consider and approve Meeting of the Board of Directors of Parmax Pharma Limited will be held on Friday 30th May 2025 at 4.00 PM inter alia to consider approve the Audited Financial Results of the quarter and Financial year ended on 31st March 2025. The board of directors of Parmax Pharma Limited has its meeting held today inter alia considered and approved the Audited financial statements of the company for the quarter and year ended on 31st March, 2025 along with statement of assets and liabilities and statement of cashflow along with auditors report issued by B A SHAH S R MEHTA & CO, statutory auditors of the company. (As Per BSE Announcement Dated on: 30/05/2025) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
